Olatoyosi Odenike, MBBS

Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy.
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Adv. 2025 Feb 19.
PMID: 39969200

Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.
Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia. Blood Adv. 2025 Feb 10.
PMID: 39928953

Imetelstat: Drugging Telomerase in Transfusion-Dependent Low and Intermediate-1 Risk MDS.
Imetelstat: Drugging Telomerase in Transfusion-Dependent Low and Intermediate-1 Risk MDS. Blood Adv. 2025 Jan 07.
PMID: 39776158

Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes.
Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes. Blood. 2024 Dec 09.
PMID: 39652823

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
PMID: 39250708

Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681

Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis.
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024 10 24; 144(17):1813-1820.
PMID: 39116296

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305.
PMID: 39110987

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes. Lancet Haematol. 2024 Nov; 11(11):e862-e872.
PMID: 39393368

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]). Mod Pathol. 2024 Dec; 37(12):100615.
PMID: 39322118